Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

On September 24, 2024 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, reported that Lynn Seely, MD, Lyell’s President & CEO, will participate on a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1 at 11:50 a.m. ET (Press release, Lyell Immunopharma, SEP 24, 2024, View Source [SID1234646841]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation can be accessed through the Investors section of the Company’s website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company’s website following the presentation date.

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

On September 24, 2024 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that its partner Takeda (TSE:​4502/​NYSE:​TAK) has received approval from the Japanese Ministry of Health, Labour and Welfare ("MHLW") to manufacture and market FRUZAQLA (fruquintinib) for previously treated metastatic colorectal cancer ("CRC") (Press release, Hutchison China MediTech, SEP 24, 2024, View Source [SID1234646840]). FRUZAQLA is the first novel targeted therapy in Japan to be approved for metastatic CRC, regardless of biomarker status, in over a decade. CRC is the most prevalent type of cancer in Japan, with an estimated 161,000 new cases and 54,000 deaths in 2023, according to the National Cancer Center’s statistics.1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FRUZAQLA has been approved for the treatment of advanced or recurrent CRC that is neither curable nor resectable and that has progressed after chemotherapy.

"Takeda has now obtained approval in Japan for FRUZAQLA, demonstrating the strength of our global data package and the potential of this novel medicine to provide a much-needed treatment option to patients with metastatic CRC," said Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED. "Takeda has been a leader in metastatic CRC treatment in Japan for over a decade and we are confident that it is well placed to bring FRUZAQLA to patients in Japan."

Dr. Takayuki Yoshino, Deputy Director of Hospital, Head, Division for the Promotion of Drug and Diagnostic Development, and Chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, added: "The approval of FRUZAQLA in Japan is significant news for patients with metastatic colorectal cancer, who have long needed additional effective treatment options. The global FRESCO-2 study demonstrated the impact that this treatment can have on patients in the clinic. The increasing availability of screening and effective therapies in Japan has been driving patient outcomes in colorectal cancer, and we hope the introduction of FRUZAQLA will offer new hope to those with the condition."

The approval by the Japanese MHLW was primarily based on results from the Phase III FRESCO-2 trial conducted in the US, Europe, Japan and Australia. Data from FRESCO-2 were published in The Lancet in June 2023. Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau. FRUZAQLA was approved in the US in November 2023 and in Europe in June 2024.

About CRC

CRC is a cancer that starts in either the colon or rectum. According to the International Agency for Research on Cancer/World Health Organization, CRC is the third most prevalent cancer worldwide, associated with more than 1.9 million new cases and 900,000 deaths in 2022. In Japan, CRC was the most common cancer, with an estimated 146,000 new cases and 60,000 deaths, in 2022.2 In Europe, CRC was the second most common cancer in 2022, with approximately 538,000 new cases and 248,000 deaths.2,3 In the US, it is estimated that 153,000 patients will be diagnosed with CRC and 53,000 deaths from the disease will occur in 2024.4 Although early-stage CRC can be surgically resected, metastatic CRC remains an area of high unmet need with poor outcomes and limited treatment options. Some patients with metastatic CRC may benefit from personalized therapeutic strategies based on molecular characteristics; however, most patients have tumors that do not harbor actionable mutations.

About the Phase III FRESCO-2 Trial

FRESCO-2 is a multiregional clinical trial conducted in the US, Europe, Japan and Australia investigating fruquintinib plus best supportive care ("BSC") versus placebo plus BSC in patients with previously treated metastatic CRC (NCT04322539). FRESCO-2 met all of its primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS), with consistent benefit among patients treated with fruquintinib, regardless of the prior types of therapies they received. Fruquintinib demonstrated a manageable safety profile in FRESCO-2, consistent with previously reported fruquintinib monotherapy studies. Adverse reactions leading to treatment discontinuation occurred in 20% of patients treated with fruquintinib plus BSC versus 21% of those treated with placebo plus BSC. Results from the study were presented at the European Society for Medical Oncology Congress (ESMO) (Free ESMO Whitepaper) in September 2022 and subsequently published in The Lancet in June 2023.10,11

About Takeda and FRUZAQLA

Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau, and markets under the brand name FRUZAQLA. FRUZAQLA received approval in the US in November 2023, in the EU in June 2024, in Switzerland in August 2024 and in Canada, Japan and the United Kingdom in September 2024. The US approval was based on data from two large, randomized, controlled Phase III trials, the multi-regional FRESCO-2 trial and the FRESCO trial conducted in China, showing consistent benefit among a total of 734 patients treated with fruquintinib. Safety profiles were consistent across trials. Regulatory applications are progressing in many other jurisdictions.

About Fruquintinib Approval in China

Fruquintinib is approved for marketing in mainland China, Hong Kong and Macau, where it is co-marketed by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE. It was included in the China National Reimbursement Drug List (NRDL) in January 2020. The approvals were based on data from the FRESCO study, a Phase III pivotal registration trial of fruquintinib in 416 patients with metastatic colorectal cancer in China, which were published in The Journal of the American Medical Association, JAMA. Since its launch in China, over 100,000 patients with colorectal cancer have been treated with fruquintinib.

About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3). VEGFR inhibitors play a pivotal role in inhibiting tumor angiogenesis. Fruquintinib was designed to have enhanced selectivity that limits off-target kinase activity, allowing for drug exposure that achieves sustained target inhibition and flexibility for potential use as part of a combination therapy. Fruquintinib has demonstrated a manageable safety profile and is being investigated in combinations with other anti-cancer therapies.

JAPAN IMPORTANT SAFETY INFORMATION

Please consult the FRUZAQLA (fruquintinib) Japan package insert (J-PI) before prescribing.

WARNING: FRUZAQLA should be administered only to patients for whom the use of FRUZAQLA is considered appropriate under the supervision of a physician with sufficient knowledge of and experience in cancer chemotherapy at a medical institution where adequate emergency care can be provided. Prior to treatment initiation, the efficacy and risks should be fully explained to the patient and/or his/her family and informed consent should be obtained; Severe gastrointestinal hemorrhage, including fatal cases, has been reported. Patients should be carefully monitored, and if any abnormalities are observed, administration of FRUZAQLA should be withheld and appropriate measures should be taken. If severe hemorrhage occurs, FRUZAQLA should not be re-administered; Gastrointestinal perforation has been reported with some fatal cases. Patients should be carefully monitored, and if any abnormalities are observed, administration of FRUZAQLA should be withheld and appropriate measures should be taken. If gastrointestinal perforation occurs, FRUZAQLA should not be re-administered.

CONTRAINDICATIONS: Patients with a history of hypersensitivity to any of the ingredients of FRUZAQLA.

IMPORTANT PRECAUTIONS: Hypertension, including hypertensive crisis, may occur. Blood pressure should be measured prior to the initiation of FRUZAQLA treatment and periodically during this treatment; Proteinuria may occur. Urinary protein should be monitored prior to the initiation of FRUZAQLA treatment and periodically during this treatment; If a surgical procedure is to be performed, patients are recommended to withhold FRUZAQLA before the surgery because wound healing may be delayed. Treatment resumption after the surgical procedure should be determined depending on the patient’s condition upon confirmation of adequate wound healing.

PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS: Patients with hyper­ten­sion: Hypertension may worsen; Patients with bleeding diathesis or abnormal coagulation system: Hemorrhagic events may occur; Patients with hemorrhage such as gastrointestinal hemorrhage: Hemorrhage may be enhanced; Patients with a complication of intra-abdominal inflammation in the gastrointestinal tract, etc.: Gastrointestinal perforation may occur; Patients with current or a history of thromboembolism: Transient ischaemic attack, thrombotic microangiopathy, pulmonary embolism, portal vein thrombosis, deep vein thrombosis, etc. may occur; Patients with severe hepatic impairment (Child-Pugh Class C): Since FRUZAQLA is metabolized mainly in the liver, blood concentrations may be increased. There have been no clinical studies conducted in patients with severe hepatic impairment; Patients with Reproductive Potential: Women of childbearing potential should be advised to use adequate contraception during treatment with FRUZAQLA and for 2 weeks after the last dose; Pregnant Women: FRUZAQLA can be administered to women who are or may be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with this treatment. In a rat embryo-fetal toxicity study, fetal abnormalities and teratogenic effects consisting of fetal external, visceral, and skeletal malformations and visceral and skeletal variations were observed at exposure levels approximately 0.05 times the exposure level (AUC) of FRUZAQLA at the maximum clinical dose (5 mg/day); Breast-feeding Women: It is advisable not to breastfeed. FRUZAQLA may pass into breast milk, and infants may experience serious adverse reactions if they are ingested through breast milk; Pediatric Use: There have been no clinical studies conducted in pediatric patients.

ADVERSE REACTIONS:

Any of the adverse reactions listed below may occur. Patients should be closely monitored, and if any such abnormalities are observed, appropriate measures should be taken, including treatment discontinuation. Clinically Significant Adverse Reactions are follows.

Hypertension: Hypertension or hypertensive crisis may occur. If an increase in blood pressure is observed, appropriate treatment such as antihypertensive drug administration should be given as necessary, and if necessary, the dose of fruquintinib should be reduced, or fruquintinib administration should be interrupted. If severe or persistent hypertension, or hypertension that cannot be controlled by routine antihypertensive therapy occurs or if a hypertensive crisis occurs, fruquintinib administration should be discontinued; Skin disorder: Skin disorder including palmar-plantar erythrodysesthesia syndrome and rash may occur; Hemorrhage: Hemorrhage including epistaxis, hematuria, gastrointestinal hemorrhage and hemoptysis may occur. Fatal outcomes have been reported; Gastrointestinal perforation: Fatal outcomes have been reported; Arterial thromboembolic events: Arterial thromboembolic events including transient ischemic attack and thrombotic microangiopathy may occur; Venous thromboembolism events: Venous thromboembolism such as pulmonary embolism, portal vein thrombosis, and deep vein thrombosis may occur; Posterior reversible encephalopathy syndrome: If headaches, convulsions, lethargy, confusion, changes in mental function, blindness or other visual disturbances, or neurological impairment are observed, fruquintinib administration should be discontinued, and appropriate measures should be taken, including blood pressure control; Arterial dissection: Arterial dissection including aortic dissection may occur.

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

On September 24, 2024 HOOKIPA Pharma Inc. (NASDAQ: HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, reported that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September 24-26, 2024 (Press release, Hookipa Pharma, SEP 24, 2024, View Source [SID1234646839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy," said Mark Winderlich, PhD, Chief Research & Development Officer. "HOOKIPA’s approach could enable HB-700 to be a widely used, multi-KRAS therapy. The preclinical dataset has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models. With IND clearance, received from the FDA in Q2 2024, HB-700 is a Phase 1 ready asset."

Presentation Details:

Oral Presentation (Virtual): Development of an Arenavirus-Based Immunotherapy for Treatment of KRAS Mutant Cancer
Session: Drug Discovery & Preclinical Development
Presentation Date/Time: Wednesday, September 25, 12:45 to 1:15 PM ET

TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival

On September 24, 2024 Eortc reported results of the EORTC-22114-40111-GITCG-ROG TOPGEAR trial of preoperative therapy for gastric and gastroesophageal junction adenocarcinoma were presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Barcelona, Spain, and simultaneously published in the New England Journal of Medicine (Press release, EORTC, SEP 24, 2024, View Source [SID1234646837]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study was conducted as an intergroup trial led by the Australasian Gastro-Intestinal Trials Group (AGITG), in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC), the Trans-Tasman Radiation Oncology Group (TROG) and the Canadian Cancer Trials Group (CCTG).

The primary objective of this phase II/III trial was to determine whether adding chemoradiotherapy to chemotherapy is superior to chemotherapy alone in the neoadjuvant setting by improving pathological complete response rates (phase II) and subsequently overall survival (phase III) in patients with resectable gastric and gastroesophageal junction cancer.

Thanks to the combined efforts of AGITG, EORTC, TROG, and CCTG, 574 patients were recruited from 70 sites across 15 countries between September 2009 and May 2021. Of these, 171 patients were recruited by 20 EORTC centres across 7 countries (Belgium, Czech Republic, France, Germany, Israël, Slovenia, and Spain).

Although a higher percentage of patients in the preoperative chemoradiotherapy group achieved a pathological complete response compared to the perioperative chemotherapy group (17% vs. 8%), the addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone. The median overall survival was 46 months with preoperative chemoradiotherapy and 49 months with perioperative chemotherapy (hazard ratio for death, 1.05; 95% confidence interval, 0.83 to 1.31), and the median progression-free survival was 31 months and 32 months, respectively. The 5-year survival rate was approximately 45% in both groups. Therefore, it is recommended that preoperative chemoradiotherapy should not become a routine standard of care.

"Cancer of the stomach, including the gastroesophageal junction, remains an aggressive and difficult-to-treat disease with a high incidence and mortality rate worldwide," said Professor Florian Lordick of University Hospital Leipzig, Germany, who co-chaired the study on behalf of the EORTC GI Tract Cancer Group. "The EORTC 22114-40111 TOPGEAR trial is an excellent example of international collaboration between academic networks globally. Although the primary endpoint of the study was not met, the trial has yielded important findings: the TOPGEAR results consolidate our European standard of care, which is perioperative chemotherapy for patients with locally advanced resectable gastric and gastroesophageal junction cancer. We are now aiming to achieve better systemic control by improving perioperative drug therapy based on a deeper understanding of individual tumour biology," Dr Lordick added.

"The results of the TOPGEAR trial will be practice-changing for many centres worldwide," said Professor Karin Haustermans of University Hospital Leuven, Belgium, who co-chaired the trial on behalf of the EORTC Radiation Oncology Group. "Preoperative chemoradiation has been used in some centres in North America for locally advanced resectable gastric cancer and has been the standard of care in Europe, Canada, and Australia for patients with locally advanced gastroesophageal junction cancer, who comprised one-third of the TOPGEAR patient cohort. Following the results of ESOPEC earlier this year, and now TOPGEAR, national and international guideline committees will need to reconsider the current role of radiation therapy in this setting. Our role as radiation oncologists is to incorporate new imaging and precision techniques into the multimodality management of patients with gastric cancer to help improve long-term outcomes for this still dangerous disease," said Dr Haustermans.

Further information on coordination and funding
The study was coordinated by the NHMRC Clinical Trials Centre (NHMRC CTC) at the University of Sydney. Funding was provided by NHMRC grants and the Cancer Australia Priority-driven Collaborative Cancer Research Scheme Grant, as well as by AGITG and NHMRC CTC, with regional funding from EORTC and CCTG through the Canadian Institutes of Health Research and the Canadian Cancer Society.

ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE) APPROVED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSIONS OR REARRANGEMENTS

On September 24, 2024 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" (tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy (Press release, Eisai, SEP 24, 2024, View Source [SID1234646836]). In Japan, it has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW), and the marketing authorization application was submitted in December 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This approval is based on data such as the results of a multicenter, open-label, single-arm clinical phase II trial (Study 201) conducted by Eisai in Japan and China. Study 201 enrolled 63 patients with unresectable advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements previously treated with gemcitabine-based combination chemotherapy. The primary endpoint of this study was objective response rate (ORR), and secondary endpoints included safety.1 This study achieved its primary endpoint and exceeded a prespecified tumor response threshold (15%) with statistical significance: ORR of patients treated with TASFYGO was 30.2% (90% confidence interval (CI): 20.7-41.0) as assessed by independent imaging review. Treatment-emergent adverse events (incidence of 25% or more) observed in this study were hyperphosphataemia (81.0%), palmar-plantar erythrodysaesthesia syndrome (44.4%), diarrhoea (36.5%), aspartate aminotransferase increase (31.7%), alanine aminotransferase increase (28.6%) and stomatitis (25.4%).

The estimated number of patients in Japan with biliary tract cancer is approximately 22,0002,3 with approximately 25% of the five-year relative survival rate,2 making it an intractable cancer with the second worst prognosis following pancreatic cancer. Since drug therapy options are limited in comparison with other cancers, it is a disease with significant unmet medical needs. FGFR2 gene fusions or rearrangements are observed in approximately 14% of intrahepatic cholangiocarcinoma, which accounts for 15-30% of biliary tract cancers.4 FGFR genetic aberrations such as the gene fusions are known to be deeply involved in the proliferation, survival and migration of cancer cells as well as tumor angiogenesis and drug resistance. As these genetic aberrations in FGFRs have been observed in various other types of cancers as well as biliary tract cancer, there is growing interest in FGFRs as a promising target for cancer therapy. TASFYGO is thought to show tumor growth inhibition by selectively inhibiting FGFR1, 2 and 3, and blocking those signals.5,6 In non-clinical studies, the antitumor activity of TASFYGO was confirmed in cells expressing the FGFR2-fusion genes, which were identified by the National Cancer Center Japan (Headquarters: Tokyo) through large-scale genomic analysis of Japanese biliary tract cancer. The companion diagnostic test to detect FGFR2 gene fusions or rearrangements for the use of TASFYGO in biliary tract cancer, "AmoyDx FGFR2 Break-apart FISH Probe Kit" by Nihon Stery, Inc. (Headquarters: Tokyo) was approved in August 2024.7

Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals, by delivering TASFYGO as a new treatment option for biliary tract cancer with FGFR2 gene fusions or rearrangements.